KRITHIKA MULLENGADA: Open Payments
NPI 1992785562 · SUCCASUNNA, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$202 in 11 payments from 8 companies in 2025. Trend: 2023 $242 · 2024 $239 · 2025 $202
Food & beverage: $202
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $54 |
| Novo Nordisk Inc | 2 | $33 |
| Exact Sciences Corporation | 1 | $32 |
| Bausch Health US, LLC | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
Products named: SHINGRIX, Cologuard Collection Kit, WELLBUTRIN, TRELEGY ELLIPTA, Ozempic, GEMTESA, RECORLEV, MOUNJARO.
Industry payments across NJ — which companies pay providers there.
